Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo

Neurobiology of Disease

Volumn 36, Issue 2, 2009, Pages 269-279

  Faraco, Giuseppe ^a   Pittelli, Maria ^a   Cavone, Leonardo ^a   Fossati, Silvia ^a   Porcu, Marco ^a   Mascagni, Paolo ^b   Fossati, Gianluca ^b   Moroni, Flavio ^a   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Italfarmaco SpA   (Italy)

Author keywords

c FOS; Microglia; microRNA 146; NF B; SOCS; Transcription

Indexed keywords

DEXAMETHASONE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ITF 2357; MICRORNA; PROTEIN C FOS; PROTEIN C JUN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 2; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; GLIA CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; TRANSCRIPTION INITIATION;

ANIMALS; ANIMALS, NEWBORN; CELL SURVIVAL; CELLS, CULTURED; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; NEUROGLIA;

EID: 70349774213     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.07.019     Document Type: Article

References (57)

1. Abel T., and Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8 (2008) 57-64
2. Allan S.M., and Rothwell N.J. Cytokines and acute neurodegeneration. Nat. Rev., Neurosci. 2 (2001) 734-744
3. Baltimore D., Boldin M.P., O'Connell R.M., Rao D.S., and Taganov K.D. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9 (2008) 839-845
4. Blanchard F., and Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov. Today 10 (2005) 197-204
5. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., and Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 31 (2007) 47-58
6. Calao M., Burny A., Quivy V., Dekoninck A., and Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem. Sci. 33 (2008) 339-349
7. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., Langley B., Khoury S.J., Stephanopoulos G., De Girolami U., Ratan R.R., Ferrante R.J., and Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164 (2005) 10-21
8. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., and Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9808-9813
9. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 149 (2007) 203-212
10. Chiarugi A., and Moskowitz M.A. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J. Neurochem. 85 (2003) 306-317
11. Corcoran L.J., Mitchison T.J., and Liu Q. A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr. Biol. 14 (2004) 488-492
12. Dimitriou I.D., Clemenza L., Scotter A.J., Chen G., Guerra F.M., and Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol. Rev. 224 (2008) 265-283
13. Dokmanovic M., and Marks P.A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96 (2005) 293-304
14. Dokmanovic M., Clarke C., and Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5 (2007) 981-989
15. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F., and Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70 (2006) 1876-1884
16. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., and Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
17. Flynt A.S., and Lai E.C. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat. Rev., Genet. 9 (2008) 831-842
18. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., and Beal M.F. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280 (2005) 556-563
19. Glauben R., Batra A., Stroh T., Erben U., Fedke I., Lehr H.A., Leoni F., Mascagni P., Dinarello C.A., Zeitz M., and Siegmund B. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 57 (2008) 613-622
20. Glozak M.A., Sengupta N., Zhang X.H., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
21. Glozak M.A., Sengupta N., Zhang X.H., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
22. Glozak M.A., Sengupta N., Zhang X.H., and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
23. Gray S.G., and Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1 (2006) 67-75
24. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., and Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 17 (2008) 169-184
25. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., and Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2041-2046
26. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
27. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8 (2001) 1505-1511
28. Kazantsev A.G., and Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev., Drug Discov. 7 (2008) 854-868
29. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., Qian X., Mills E., Berghs S.C., Carey N., Finn P.W., Collins L.S., Tumber A., Ritchie J.W., Jensen P.B., Lichenstein H.S., and Sehested M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409 (2008) 581-589
30. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
31. Langley B., Gensert J.M., Beal M.F., and Ratan R.R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 41-50
32. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., Dona G., Fossati G., Sozzani S., Azam T., Bufler P., Fantuzzi G., Goncharov I., Kim S.H., Pomerantz B.J., Reznikov L.L., Siegmund B., Dinarello C.A., and Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2995-3000
33. Liu H., Hu Q., Kaufman A., D'Ercole A.J., and Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res. 86 (2008) 537-543
34. MacDonald J.L., and Roskams A.J. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev. Dyn. 237 (2008) 2256-2267
35. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 26 (2007) 1351-1356
36. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev., Cancer 6 (2006) 38-51
37. Nusinzon I., and Horvath C.M. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci. STKE 2005 (2005) re11
38. Pedersen I., and David M. MicroRNAs in the immune response. Cytokine 43 (2008) 391-394
39. Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., and Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22 (2006) 40-49
40. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., Maeda Y., Tawara I., Krijanovski O., Gatza E., Liu C., Malter C., Mascagni P., Dinarello C.A., and Ferrara J.L. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118 (2008) 2562-2573
41. Ren M., Leng Y., Jeong M., Leeds P.R., and Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004) 1358-1367
42. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown Jr. R.H., and Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93 (2005) 1087-1098
43. Saha R.N., and Pahan K. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. 13 (2006) 539-550
44. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., and Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006) 435-443
45. Schickel R., Boyerinas B., Park S.M., and Peter M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27 (2008) 5959-5974
46. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., and Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66 (2006) 1277-1281
47. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J., and Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 11 (2008) 1024-1034
48. Suuronen T., Huuskonen J., Pihlaja R., Kyrylenko S., and Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem. 87 (2003) 407-416
49. Suuronen T., Nuutinen T., Huuskonen J., Ojala J., Thornell A., and Salminen A. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm. Res. 54 (2005) 194-203
50. Suuronen T., Huuskonen J., Nuutinen T., and Salminen A. Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. Neurochem. Int. 49 (2006) 610-618
51. Taganov K.D., Boldin M.P., Chang K.J., and Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12481-12486
52. Villagra A., Cheng F., Wang H.W., Suarez I., Glozak M., Maurin M., Nguyen D., Wright K.L., Atadja P.W., Bhalla K., Pinilla-Ibarz J., Seto E., and Sotomayor E.M. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10 (2009) 92-100
53. Witt O., Deubzer H.E., Milde T., and Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett. 277 (2008) 8-21
54. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
55. Yang M.S., Min K.J., and Joe E. Multiple mechanisms that prevent excessive brain inflammation. J. Neurosci. Res. 85 (2007) 2298-2305
56. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev., Drug Discov. 5 (2006) 37-50
57. Zhang B., West E.J., Van K.C., Gurkoff G.G., Zhou J., Zhang X.M., Kozikowski A.P., and Lyeth B.G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res. 1226 (2008) 181-191